Capricor therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Capricor therapeutics Contact Number

Contact Us Capricor Capricor Therapeutics

9 hours ago Capricor.com Show details

310-358-3200Contact Information: Capricor Therapeutics. 8840 Wilshire Blvd 2nd Floor Beverly Hills, CA 90211 Tel: +310-358-3200. Careers. Capricor is always searching for highly qualified candidates to join our team. For more information please email us at [email protected] or click here to view a list of available positions.

1. Capricor TherapeuticsCapricor is Developing Transformative Cell and Exosome-based Therapeutics for the …

Category: Contact SupportShow more

Capricor Therapeutics, Inc. Engineering Contacts Business

7 hours ago Adapt.io Show details

Find the Capricor Therapeutics, Inc. company's Engineering team/department contact details such as business emails, phone numbers, web address and other …

Category: Contact SupportShow more

Capricor Therapeutics Crunchbase Company Profile & …

8 hours ago Crunchbase.com Show details

(310) 358-3200Contact Email [email protected]capricor.com Phone Number (310) 358-3200 Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases.

Founded: 2005
Founder: Dr Linda Marban

Category: Contact NumberShow more

Company Overview Capricor Capricor Therapeutics

8 hours ago Capricor.com Show details

Our Story Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways.

Category: Contact NumberShow more

Investors Capricor Capricor Therapeutics

1 hours ago Capricor.com Show details

Corporate Overview. Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is

Category: Contact NumberShow more

Vikki Robertson's email & phone Capricor Therapeutics

4 hours ago Rocketreach.co Show details

Vikki Robertson's email address v*****@capricor.com Show email & phone number >>> Rocketreach finds email, phone & social media for 450M+ professionals. Try for free at rocketreach.co

Category: Phone NumberShow more

CAPRICOR THERAPEUTICS, INC. (Form: 8K, Received: 04/30

5 hours ago Content.edgar-online.com Show details

659-21-0582None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich / Raquel Cona KCSA Strategic Communications [email protected] / [email protected] 212.896.1241 / 212.896.1204 Investor Contact: Joyce Allaire LifeSci Advisors, LLC

Category: Contact NumberShow more

Capricor (CAPR) What's next after the earnings call

5 hours ago Kametresearch.com Show details

Another factor that was mentioned was the number of clinical sites – TWENTY – which is a lot more than the Phase – 2 (Seven Sites) and INSPIRE (Four Sites). From experience, I can tell you that a baby biotech like Capricor talking about 20 sites is just not possible without Big Pharma Support – so it would not surprise me if something

Category: Contact NumberShow more

Capricor Therapeutics Reports Second Quarter 2021

Just Now Finance.yahoo.com Show details

Additionally, in the second quarter of 2021, Capricor raised approximately $1.0 million in net proceeds through issuances of common stock at an average price of …

Category: Contact NumberShow more

CAPRICOR THERAPEUTICS : Management's Discussion and

Just Now Marketscreener.com Show details

(310) 358-3200Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. Our telephone number is (310) 358-3200 and our Internet address is www.capricor.com. Contact; Legal information

Category: Contact NumberShow more

Capricor Therapeutics Signs Exclusive Worldwide License

Just Now Stocktitan.net Show details

212.896.1241None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich / Raquel Cona KCSA Strategic Communications [email protected] / [email protected] 212.896.1241 / 212.896.1204. Investor Contact: Joyce Allaire LifeSci Advisors, LLC jallaire

Category: Contact NumberShow more

Events & Presentations Capricor Capricor Therapeutics

3 hours ago Capricor.com Show details

Events & Presentations. Date. Events, Presentations & Webcasts. Sept. 13, 2021. Capricor’s Presentation at the H.C. Wainwright 23rd Annual Global Investment Conference – Webcast. Aug. 12, 2021. Capricor Therapeutics Second Quarter 2021 Financial Results and Corporate Update Conference Call. Jun. 22, 2021. Capricor Therapeutics Presentation

Category: Contact NumberShow more

Capricor Therapeutics Reports Fourth Quarter and Full Year

Just Now Finance.yahoo.com Show details

LOS ANGELES, March 11, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for

Category: Contact NumberShow more

CAPR – RMAT designation! Good P2 Results with nice cash

3 hours ago Frugalnorwegian.com Show details

Capricor Therapeutics slumps 9% on $75M stock offering - June 21, 2021 Capricor shares rise on license agreement with Johns Hopkins University - Apr 29, 2021 Muscular dystrophy treatment showing promise with COVID-19 patients at Cedars-Sinai - May 12, 2020

Category: Contact NumberShow more

Capricor Therapeutics Number of Employees 20062021 CAPR

8 hours ago Macrotrends.net Show details

Capricor Therapeutics number of employees from 2006 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Contact NumberShow more

All News for CAPR : Capricor Therapeutics, Inc. Zacks.com

Just Now Zacks.com Show details

Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates. by Zacks Equity Research Published on May 14,2020. Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11

Category: Contact NumberShow more

Capricor Therapeutics Reports Second Quarter 2021

7 hours ago Apnews.com Show details

617.435.6602Investor Contact: Joyce Allaire LifeSci Advisors, LLC [email protected] 617.435.6602. Company Contact: AJ Bergmann, Chief Financial Officer [email protected]capricor.com 310.358.3200. CAPRICOR THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

Category: Contact NumberShow more

CAPR Capricor Therapeutics Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

About Capricor Therapeutics. Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company focused on developing transformative cell- and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in

Category: Contact NumberShow more

Capricor Therapeutics YouTube

3 hours ago Youtube.com Show details

Linda Marban, Ph.D., President and CEOLos Angeles, CA(NASDAQ: CAPR)Capricor Therapeutics is a clinical-stage biotechnology company developing biological ther

Category: Contact NumberShow more

Capricor Therapeutics Awarded $2.4 Million from U.S

6 hours ago Prnewswire.com Show details

310-358-3200For more information, please contact: Corporate Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 [email protected] Investor Relations Argot Partners Kimberly

Category: Contact NumberShow more

Kuur Therapeutics Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Show details

44 20 7554Legal Name Cell Medica Limited. Company Type For Profit. Contact Email [email protected] Phone Number 44 20 7554 4070. Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology

Category: Contact NumberShow more

Capricor Therapeutics Reports First Quarter 2021 Financial

9 hours ago Finance.yahoo.com Show details

Financial Results for First Quarter 2021. The Company reported a net loss of approximately $5.2 million, or $0.23 per share, for the first quarter of 2021, compared to …

Category: Contact NumberShow more

Capricor Therapeutics Announces Positive Final Data From

2 hours ago Finance.yahoo.com Show details

More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, …

Category: Contact NumberShow more

Capricor Therapeutics : Reports Second Quarter 2021

9 hours ago Marketscreener.com Show details

Financial Results for Second Quarter 2021. Revenues in conjunction with collaborations and grants: Capricor's primary sources of revenues were from collaborative payments received from clinical trial arrangements and grant awards. For the three months ended June 30, 2021, the Company reported revenue of approximately $200,000 compared with approximately $50,000 for the three …

Category: Contact NumberShow more

Capricor Therapeutics Funding, Financials, Valuation

7 hours ago Crunchbase.com Show details

Capricor Therapeutics has raised a total of $63.1M in funding over 9 rounds. Their latest funding was raised on Dec 21, 2019 from a Post-IPO Equity round. Capricor Therapeutics is registered under the ticker NASDAQ:CAPR . Capricor Therapeutics is funded by 7 investors. National Institutes of Health and U.S. Department of Defense are the most

Category: Contact NumberShow more

Biotech catalyst calendars and drug pipelines

Just Now Biopharmcatalyst.com Show details

855-327-6838Capricor will host a conference call and webcast with slides today, May 13, 2020, at 8:00 a.m. ET to discuss the top-line results of the HOPE-2 study. To participate in the conference call, please dial 855-327-6838 (domestic) or 604-235-2082 (international) and reference the access code: 10009621.

Category: Tech SupportShow more

Capricor to Present at the American Society of Gene and

4 hours ago Finance.yahoo.com Show details

None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich / Raquel Cona. KCSA Strategic

Category: Contact NumberShow more

CAPR Stock Message Board Capricor Therapeutics Inc

6 hours ago Investorshangout.com Show details

CAPR Stock Message Board for Investors. Capricor Therapeutics Inc. Stock Price, News and Company Updates. Message Board Total Posts: 43

Category: Contact NumberShow more

Capricor Therapeutics : to Present at the Upcoming

5 hours ago Marketscreener.com Show details

212.896.1241CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich / Raquel Cona KCSA Strategic Communications [email protected] / [email protected] 212.896.1241 / 212.896

Category: Contact NumberShow more

Capricor Therapeutics Announces Positive Final Data From

Just Now Globenewswire.com Show details

Conference Call and Webcast Details. Capricor will host a conference call and webcast with slides today, September 24, 2021, at 8:30 a.m. ET to discuss the final data of the HOPE-2 …

Category: Contact NumberShow more

Exosome Technologies: Recent Surge in R&D with Capricor

8 hours ago Store.marketline.com Show details

3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40. 3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41. 3.5.10 CIL-15001 and CIL-15002 - Ciloa 42. 3.5.11 ExoPr0 - ReNeuron Group Plc 42. 3.5.12 MVAX-001 - MolecuVax Inc. 43. 3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44

Category: Tech SupportShow more

What Do Analysts Have To Say About Capricor Therapeutics

2 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 22.86 million. CAPR does have institutional investors; and they hold 15.30% of the stock. Capricor Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

Capricor Therapeutics Reports Fourth Quarter and Full Year

3 hours ago Globenewswire.com Show details

Fourth Quarter and Full Year Financial Results. The Company reported a net loss of approximately $4.2 million, or $0.21 per share, for the fourth

Category: Contact NumberShow more

Contact Us Bicycle Therapeutics

7 hours ago Bicycletherapeutics.com Show details

Contact IR We are a transatlantic company with headquarters in the vibrant life science cluster of Cambridge, U.K. and many key functions located in the biotech hub of Boston, Mass., U.S.A. We are a transatlantic company with headquarters in the vibrant life science cluster of Cambridge, U.K. and many key functions located in the biotech hub of

Category: Contact SupportShow more

Capricor To Present Preclinical Data for ExosomemRNA

4 hours ago Globenewswire.com Show details

More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, …

Category: Contact NumberShow more

Capricor Awarded $3.4 Million Grant from California

1 hours ago Prnewswire.com Show details

Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine. LOS ANGELES, March 17, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR ), a …

Category: Contact NumberShow more

CAPRICOR THERAPEUTICS INC : All Information and News

1 hours ago Marketscreener.com Show details

3.0253. USD. +10.01%. 08/13. CAPRICOR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) AQ. 08/12. CAPRICOR THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Corporate Update (Form 8-K) PU.

Category: Contact NumberShow more

Capricor Stock Price CAPR Macroaxis

2 hours ago Macroaxis.com Show details

Capricor Therap is selling at 4.26 as of the 29th of September 2021; that is -1.84 percent down since the beginning of the trading day. The stock's lowest day price was 4.13. Get the latest Capricor Therap detailed stock quotes, stock trade data, stock price info, and performance analysis, including Capricor Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

Capricor Therapeutics to Present at the Upcoming Investor

5 hours ago Globenewswire.com Show details

More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, …

Category: Contact NumberShow more

Capricor To Present Preclinical Data for ExosomemRNA

1 hours ago Stocktitan.net Show details

212.896.1241None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich / Raquel Cona KCSA Strategic Communications [email protected] / [email protected] 212.896.1241 / 212.896.1204. Investor Contact: Joyce Allaire LifeSci Advisors, LLC jallaire

Category: Contact NumberShow more

Stock Market Daily: Capricor Therapeutics (CAPR

4 hours ago Stockmarketdaily.co Show details

Capricor Therapeutics Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy. Shares of Capricor Therapeutics traded up $0.14 on Wednesday, reaching $4.12. 161849 shares of the stock traded hands, compared to its average volume of 1259731.

Category: Contact NumberShow more

Capricor Therapeutics to Present at The LD 500 Virtual

Just Now Charlottenews.net Show details

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ('Capricor') (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 9:20 …

Category: Contact NumberShow more

Capricor Therapeutics : Announces Positive Final Data From

Just Now Marketscreener.com Show details

212.896.1241CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich / Raquel Cona KCSA Strategic Communications [email protected] / [email protected] 212.896.1241 / 212.896

Category: Contact NumberShow more

Capricor Therapeutics Inc. (CAPR) Outlook And Short Term

5 hours ago Marketingsentinel.com Show details

Capricor Therapeutics Inc. (NASDAQ:CAPR) has a beta value of 6.49 and has seen 1.48 million shares traded in the last trading session. The company, currently valued at $99.01M, closed the last trade at $4.48 per share which meant it lost -$0.75 on the day or …

Category: Contact NumberShow more

Joshua Kazam CoFounder and Director @ Kronos Bio

8 hours ago Crunchbase.com Show details

Joshua is the Co-Founder and Director of Kronos Bio. Mr. Kazam is a co-founder and Partner of Two River. He also serves as an Officer and Director of Riverbank Capital Securities, Inc., a FINRA member broker-dealer ("Riverbank"). Prior to co-founding Two River, he was employed by a venture capital firm specializing in biotechnology.

Category: Contact NumberShow more

Capricor Announces Positive TopLine Final Results from

2 hours ago Globenewswire.com Show details

Capricor will host a conference call and webcast with slides today, May 13, 2020, at 8:00 a.m. ET to discuss the top-line results of the HOPE-2 study. To participate in the conference call, please

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is capricor Therapeutics Inc?

Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases.

What kind of cell therapy does capricor have?

Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform.

When do hope 2 results come out capricor?

HOPE-2 is Capricor's randomized, double-blind, placebo-controlled, Phase II clinical trial in 20 patients with late-stage Duchenne muscular dystrophy (DMD), conducted at nine sites in the U.S. The late-breaking results will be presented in an oral session on Sept. 24, 2021, from 4:15 to 5 p.m…

Popular Brands

Costco
Cisco
Ccu
Cae